Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 6;10:315. doi: 10.3389/fimmu.2019.00315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Oostenbrink, Jol-van der Zijde, Kielsen, Jansen-Hoogendijk, Ifversen, Müller, Lankester, van Halteren, Bredius, Schilham and van Tol.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Box plots of serum/plasma concentration of total Rabbit IgG (total ATG) and active ATG in ATG-GENZ (Genzyme, red) and ATG-FRES (Fresenius, green) treated patients. (A) Total Rabbit IgG concentration in ATG-FRES treated patients at week 0 (day of graft infusion) and week +3 (expected time of neutrophil engraftment) is significantly higher in comparison with ATG-GENZ treated patients. (B) Active ATG concentration at week 0 in ATG-FRES treated patients is significantly higher in comparison with ATG-GENZ treated patients, but at week +3 the serum/plasma level of active ATG in ATG-FRES treated patients is lower than in ATG-GENZ treated patients (0.17 vs. 0.65 AU/mL).